From Research findings to Therapeutic opportunity:
The study presented here suggests that Curcumin, by increasing the expression of its target genes, it may: (i) inhibit WNT-SOX9 oncogenic pathway; (ii) decrease oncogenic β-catenin protein levels; (iii) decrease H. pylori-induced gastric cancer cell proliferation; (iv) inhibit acquisition of tumor-initiating stem-cell properties; and (v) decrease chemoresistance.
Thereby, it may inhibit proliferation of H.Pylori-induced gastric cancer cells. Thus, pharmacological formulations encompassing “Curcumin or analogues or Curcumin in combination with any other anticancer drugs” may be used to inhibit cancer progression (Fig. 1).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed information: How Curcumin inhibits the WNT-SOX9 oncogenic pathway?
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at email@example.com
# Research cooperation
Citation: Boominathan, L., Natural product-derived therapy for H. pylori –induced Gastric cancer: Curcumin, one of the main components of Turmeric, inhibits WNT-SOX9 pathway, decreases oncogenic β-catenin levels, suppresses H. pylori-induced gastric cancer proliferation, inhibits acquisition of tumor-initiating stem-cell properties and decreases chemoresistance via up regulation of its target gene, 3/January/2017, 1.23 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org